On March 31st, Oscotec signed a technology transfer agreement with Kanaph Therapeutics to acquire the exclusive global license for the latter's KNP-502, an EP2/4 dual inhibitor for treating cancer.

Under the accord, Kanaph will receive a down payment of 2 billion won ($1.6 million), various milestones and royalties, or distribution of profits if Oscotec further licenses out the drug to a multinational pharmaceutical company.

According to Oscotec, EP2/4, targeted by KNP-502, is a Prostaglandin E2 (PGE2) receptor secreted by cancer cells into the tumor microenvironment during malignancy.

http://www.koreabiomed.com/news/articleView.html?idxno=13411